Theravance Biopharma Stock News

DUBLIN , April 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET (10:30 am P

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

Theravance Biopharma Inc (NASDAQ: TBPH) revealed results from the second Phase 3 study assessing ampreloxetine compared to placebo for symptomatic nOH.  Neurogenic orthostatic hypotension (nOH) is

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the primary endpoint was not statistica

Theravance Biopharma Inc. (NASDAQ:TBPH) shares, rose in value on Friday, 03/11/22, with the stock price down by -1.20% to the previous day’s close as strong demand from buyers drove the stock to $9.89. Actively observing the price movement in the last trading, the stock closed the session at $10.01, falling within a range of $9.87 … Is Now A Good Time To Invest In Theravance Biopharma Inc. (NASDAQ: TBPH)? Read More »

Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

Theravance Biopharma (NASDAQ: TBPH ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Also check this: Tesla And 4 Other Stocks Sold By Insiders Earnings Theravance Biopharma beat estimated earnings … Full story available on Benzinga.com

Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q4 2021 Results - Earnings Call Transcript

Theravance Biopharma press release (TBPH): Q4 GAAP EPS of -$0.43 misses by $0.12.Revenue of $14.95M (-20.2% Y/Y) beats by $1.39M.The company expects FY2022 R&D expense of $45M to…

DUBLIN, Feb. 23, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021. "While COVID continues to impact communities around the country and…

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.